A Nomogram for Identifying HR+/Her2- Breast Cancer Patients with Positive Sentinel Lymph Nodes and Omitted Axillary Lymph Node Dissection Who Need Abemaciclib Therapy
Medical Science Monitor · 2023
DOI: 10.12659/msm.940124 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Science Monitor, 2023. Verfasst von Hanzhao Yang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland). Hauptthemen laut MEDLINE: Sentinel Lymph Node, Breast Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND The efficacy of abemaciclib in high-risk patients with early-stage HR+/Her2- breast cancer has been verified by MonarchE. However, accurately determining the number of axillary lymph node (ALN) metastases remains challenging. The Z0011 trial changed the axillary management strategy, eliminating the need for axillary lymph node dissection (ALND) in patients with 1-2 sentinel lymph node (SLN) metastases. Therefore, further exploration is needed to identify patients who could benefit from abemaciclib therapy. MATERIAL AND METHODS This retrospective study included cT1-2N0M0 HR+/Her2- patients with 1-2 positive SLNs who underwent ALND. Clinicopathological data were collected, and logistic regression analyses identified independent predictors for ≥4 positive ALNs. A predictive nomogram was developed, and discrimination and calibration were evaluated using the C-index and calibration curve. Clinical efficacy was assessed using decision curve analysis (DCA). RESULTS We enrolled 444 patients, with 77 (17.3%) having ≥4 positive ALNs. Independent predictors for ≥4 positive ALNs included abnormal ALN on ultrasound, mammographic calcifications, T stage, and the number of positive SLNs. The nomogram demonstrated an AUC of 0.777 (95% CI: 0.735-0.815, P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland).
Zitieren
APA
Yang, H., Sun, Y., Wang, P., Qiao, J., Li, L., Lu, Z., Sun, X., Zhang, C., Chen, X., Yan, M., Cui, S., Wang, C., & Liu, Z. (2023). A Nomogram for Identifying HR+/Her2- Breast Cancer Patients with Positive Sentinel Lymph Nodes and Omitted Axillary Lymph Node Dissection Who Need Abemaciclib Therapy. Medical Science Monitor. https://doi.org/10.12659/msm.940124
Vancouver
Yang H, Sun Y, Wang P, Qiao J, Li L, Lu Z, et al. A Nomogram for Identifying HR+/Her2- Breast Cancer Patients with Positive Sentinel Lymph Nodes and Omitted Axillary Lymph Node Dissection Who Need Abemaciclib Therapy. Medical Science Monitor. 2023. doi:10.12659/msm.940124
BibTeX
@article{Yang2023,
author = {Yang, Hanzhao and Sun, Yadong and Wang, Peili and Qiao, Jianghua and Li, Lianfang and Lu, Zhenduo and Sun, Xianfu and Zhang, Chongjian and Chen, Xiuchun and Yan, Min and Cui, Shude and Wang, Chengzheng and Liu, Zhenzhen},
title = {A Nomogram for Identifying HR+/Her2- Breast Cancer Patients with Positive Sentinel Lymph Nodes and Omitted Axillary Lymph Node Dissection Who Need Abemaciclib Therapy},
journal = {Medical Science Monitor},
year = {2023},
doi = {10.12659/msm.940124}
}
EUVIMED